Business Boom for Autoscribe
News Dec 23, 2014
Autoscribe Ltd, believes that its continued growth is due in no small part to the pricing structure and configurability of its flagship Matrix Gemini LIMS. In results announced for the most recent financial year, increased turnover in the UK was also accompanied by an increase in orders of more than 30% from the US office, with both operations reporting increased profitability.
Autoscribe’s Managing Director, John Boother, said: “In a recent survey of our customers, ‘Value for money’ and ‘The ability to configure for any type of testing’ were the overwhelming reasons given for choosing our Matrix Gemini products.”
“The company has shown sustained growth over the two most recent financial years, and even more encouragingly, we are already seeing a further UK business growth of close to 30% in the current financial year,” he continued. “Not only that, our work in progress (awaiting invoicing) is also at a record high. The increases in order intake and profitability represent an excellent return following a significant period of investment, particularly in the US organization.”
“Product and pricing benefits are only part of the story, however,” he concluded. “We also understand the importance of the relationship between our sales team and our customers. The customer survey also showed that 87% of purchasers rated our sales team at 8/10 or better with more than 50% of these giving them a score of 10/10.”
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE
Mood disorders like major depressive disorder (MDD) and bipolar disorder are often complex and hard to diagnose, especially among youth when the illness is just evolving. This can make decisions about medication difficult. In a collaborative study by Lawson Health Research Institute, The Mind Research Network and Brainnetome Center, researchers have developed an artificial intelligence (AI) algorithm that analyzes brain scans to better classify illness in patients with a complex mood disorder and help predict their response to medication.